237 related articles for article (PubMed ID: 32627316)
21. Diabetes mellitus in Bardet Biedl syndrome.
Pomeroy J; Offenwanger KM; Timmler T
Curr Opin Endocrinol Diabetes Obes; 2023 Feb; 30(1):27-31. PubMed ID: 36476576
[TBL] [Abstract][Full Text] [Related]
22. The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population.
Mujahid S; Hunt KF; Cheah YS; Forsythe E; Hazlehurst JM; Sparks K; Mohammed S; Tomlinson JW; Amiel SA; Carroll PV; Beales PL; Huda MSB; McGowan BM
J Clin Endocrinol Metab; 2018 May; 103(5):1834-1841. PubMed ID: 29409041
[TBL] [Abstract][Full Text] [Related]
23. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
Falls BA; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
[TBL] [Abstract][Full Text] [Related]
24. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
[TBL] [Abstract][Full Text] [Related]
25. Renal transplantation in Bardet-Biedl Syndrome.
Haws RM; Joshi A; Shah SA; Alkandari O; Turman MA
Pediatr Nephrol; 2016 Nov; 31(11):2153-61. PubMed ID: 27245600
[TBL] [Abstract][Full Text] [Related]
26. Could setmelanotide be the game-changer for acquired hypothalamic obesity?
van Santen HM; Denzer C; Müller HL
Front Endocrinol (Lausanne); 2023; 14():1307889. PubMed ID: 38239988
[TBL] [Abstract][Full Text] [Related]
27. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
Wabitsch M; Farooqi S; Flück CE; Bratina N; Mallya UG; Stewart M; Garrison J; van den Akker E; Kühnen P
J Endocr Soc; 2022 Jun; 6(6):bvac057. PubMed ID: 35528826
[TBL] [Abstract][Full Text] [Related]
28. Renal features of Bardet Biedl syndrome: A single center experience.
Atmış B; Karabay-Bayazıt A; Melek E; Bişgin A; Anarat A
Turk J Pediatr; 2019; 61(2):186-192. PubMed ID: 31951329
[TBL] [Abstract][Full Text] [Related]
29. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis.
Ferraz Barbosa B; Aquino de Moraes FC; Bordignon Barbosa C; Palavicini Santos PTK; Pereira da Silva I; Araujo Alves da Silva B; Cristine Marques Barros J; Rodríguez Burbano RM; Pereira Carneiro Dos Santos N; Rodrigues Fernandes M
J Pers Med; 2023 Oct; 13(10):. PubMed ID: 37888071
[TBL] [Abstract][Full Text] [Related]
31. The importance of renal impairment in the natural history of Bardet-Biedl syndrome.
O'Dea D; Parfrey PS; Harnett JD; Hefferton D; Cramer BC; Green J
Am J Kidney Dis; 1996 Jun; 27(6):776-83. PubMed ID: 8651240
[TBL] [Abstract][Full Text] [Related]
32. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
33. Setmelanotide: what does it mean for clinical care of patients with obesity?
Ryan DH
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):933-935. PubMed ID: 33137294
[No Abstract] [Full Text] [Related]
34. Sleep disordered breathing in Bardet-Biedl Syndrome.
Yeung JC; Katwa UA; Lee GS
Int J Pediatr Otorhinolaryngol; 2017 Nov; 102():127-132. PubMed ID: 29106859
[TBL] [Abstract][Full Text] [Related]
35. Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers.
Dubern B; Lourdelle A; Clément K
JCEM Case Rep; 2023 May; 1(3):luad041. PubMed ID: 37908575
[TBL] [Abstract][Full Text] [Related]
36. Establishing a connection between cilia and Bardet-Biedl Syndrome.
Mykytyn K; Sheffield VC
Trends Mol Med; 2004 Mar; 10(3):106-9. PubMed ID: 15106604
[TBL] [Abstract][Full Text] [Related]
37. [Algorithm for the molecular analysis of Bardet-Biedl syndrome in Spain].
Castro-Sánchez S; Álvarez-Satta M; Pereiro I; Piñeiro-Gallego MT; Valverde D
Med Clin (Barc); 2015 Aug; 145(4):147-52. PubMed ID: 25087209
[TBL] [Abstract][Full Text] [Related]
38. [Current status and implication of research on Bardet-Biedl syndrome].
Shen T; Yan XM; Xiao CJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):570-3. PubMed ID: 24078572
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
